Plastoquinonyl decyl triphenylphosphonium

Drug Profile

Plastoquinonyl decyl triphenylphosphonium

Alternative Names: Plastomitin; SkQ-1; SkQ1 eye drops; SkQ1 pill; Visomitin

Latest Information Update: 17 Nov 2016

Price : $50

At a glance

  • Originator Mitotech
  • Class Anti-inflammatories; Benzoquinones; Eye disorder therapies; Neuropsychotherapeutics; Organophosphorus compounds; Small molecules
  • Mechanism of Action Antioxidants; Electron transport chain complex protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Dry eyes
  • Phase I Neurodegenerative disorders
  • Clinical Phase Unknown Unspecified
  • Preclinical Inflammation; Uveitis; Wet age-related macular degeneration

Most Recent Events

  • 16 Nov 2016 Preclinical trials in Wet age-related macular degeneration in Russia (Ophthalmic) (Mitotech pipeline, November 2016)
  • 09 Sep 2016 Mitotech receives patent allowance for Plastoquinonyl decyl triphenylphosphonium in USA
  • 25 Jan 2016 Clinical trials in Undefined indication in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top